

Effect of Lycopene Supplementation on Osteoblastic Cells

¹ Purnima Dey Sarkar, Professor and Head, Department of Biochemistry, M G M Medical College, Indore, M P, INDIA
deanmgmmc.indore@rediffmail.com, pihu47@yahoo.co.in

² Ashok Sahu, Asst professor, Department of Biochemistry, NSCB Medical College, Jabalpur, M.P., 482003
E mail- asahu888@yahoo.co.in, asahu888@gmail.com

^{3*} Trapti Gupta, M Sc (Medical Biochemistry), Asst professor, Department of Biochemistry, N S C B Medical College, Jabalpur, M P, 482003, INDIA

*Corresponding Author: Name: Ms Trapti Gupta
Department of Biochemistry,
N S C B Medical (Govt.) College, Jabalpur, M P, 482003, INDIA
09981066848, traptigupta_3@rediffmail.com

Summary

Lycopene is a carotenoid phytochemical antioxidant found in tomatoes. Oxygen derived free radicals are the most reactive species cause oxidative stress. It is one of the major causes of osteoporosis with increased lipid peroxidation, distorted osteoblastic cell activity and antioxidant status. Supplementation of lycopene improves antioxidant status by maintaining osteoblastic cell activity because it has a singlet oxygen quenching ability twice as high as that of β -carotene and 10 times higher than that of α -tocopherol therefore believe to improve the condition of osteoporotic patients. The present study included 60 clinically diagnosed osteoporotic patients, age between 40-60 years. 60 patient matched healthy subjects were taken as control. After estimation of base line osteoblastic markers including ALP, Pi and Ca^{++} , lipid peroxidation product MDA, oxidative stress biomarkers like SOD, GPX, GR, GSH, antioxidant vitamins A, C and E, patients supplemented 180gm of tomato products. After 90 days of lycopene supplementation patients were reassessed for all biochemical parameters included in the study.

The results of study revealed increased ALP while decreased Pi and Ca^{++} in osteoporotic patients but after lycopene supplementation levels were improved without any significant change in inorganic phosphorus. Decreased lipid peroxidation and oxidative stress were confirmed by MDA and recovered levels of SOD, GPX, GR, GSH, Vitamin A, Vitamin E and Vitamin C respectively in patients.

The results of present study concluded that dietary intake of tomato lycopene is beneficial for bone health in osteoporotic patients as it acts as an external antioxidant to fulfill the body need. It is confirmed by improved levels of osteoblastic markers and antioxidants after lycopene supplementation.

Key Words: - Osteoporosis; Oxidative stress; Lycopene, Alkaline Phosphatase (ALP); Inorganic Phosphorus (Pi); Free or ionic calcium; MDA; GSH; SOD; Vitamin C; Vitamin E.

Running title: "Osteoprotective effect of lycopene"

Introduction

Bone is a dynamic tissue that is continuously renewed all over the life by the process of bone remodeling, which involves the coupled events of removal of old bone by osteoclasts and formation of new bone by osteoblasts.^{1,2} The remodeling process is the result of interactions, involving these cells and multiple molecular agents like hormones, growth factors, and cytokines. Disturbances in metabolic process due to oxidative stress and free radical generation alter the process of bone remodeling and lead to bone diseases.^{3,4} Osteoporosis is a major metabolic bone disorder characterized by low bone mass and micro architecture deterioration of bone tissue causing enhanced bone fragility lead to increased risk of fracture therefore it is known as “silent disease”⁵ and affects 1 in 4 women and 1 in 8 men.⁶ Osteoporotic fractures are a major cause of morbidity and disability in the elderly, these fractures also contribute to a considerable economic burden on health services. Only in India about 60 million adults have osteoporosis and approximately 2-3 million cases are being added annually⁷. There are several risk factors for osteoporosis including non modifiable and modifiable risk factors in which non modifiable risk factors are asian race, old age, female sex, inactivity, lack of weight bearing exercise. Modifiable risk factors include smoking, excessive alcohol consumption, excessive caffeine consumption, deficiency of calcium, lack of sunlight exposure, diabetes mellitus, hyperparathyroidism and oxidative stress.^{8,9}

Of these risk factors oxidative stress represents an imbalance between the production of reactive oxygen species and a biological system's ability to readily detoxify the reactive intermediates or to repair the resulting damage.^{10,11,12,13} It may be prevented by lycopene supplementation. Lycopene is a 40 carbon acyclic carotenoid containing 11 conjugated double bonds, a phytochemical found in tomatoes and other red fruit, lycopene configuration enables it to inactivate free radical.

Oxygen derived free radicals are the most reactive species and as an antioxidant lycopene has a singlet oxygen quenching ability twice as high as that of β -carotene and 10 times higher than that of α -tocopherol¹⁴, lycopene participate in a host of chemical reactions to protect critical cellular biomolecules including lipid, proteins and DNA.^{15,16} Lycopene from processed tomato products appears to be more bioavailable than from raw tomatoes¹⁷. Comparative bioavailability of lycopene from diverse tomato products such as paste, juice, ketchup, sauce and soup are not known but lycopene from tomato paste was shown to be more bioavailable than from fresh tomatoes¹⁸. Dietary lipids and heat treatment formulate lycopene more bioavailable and after processing lycopene release from the food matrix. Heat-induced isomerization from all trans to cis conformation enhance lycopene bioavailability^{15,19}

Despite several epidemiological and experimental evidences showing antioxidant status in osteoporotic patients, there are no data on the effect of lycopene in patients suffering from osteoporosis in India so the aim of the study is to access the consequences of lycopene supplementation in osteoporotic patients by evaluating antioxidant vitamins and enzymes status.

Materials and Methods

The present study includes 60 patients having osteoporosis (irrespective of etiology), age between 40-60 years, nonsmokers, with no history of chronic systemic illness and 60 patients matched healthy subjects were taken as control. All subjects were selected from outpatient department of NSCB Medical College Jabalpur M.P. Patients already on antioxidant supplementation at the time of enrollment were excluded. After overnight 12 hours fasting; blood sample (10 ml whole blood) was collected, under aseptic conditions, from both the patients and control. Samples were analyzed for biochemical markers within 3 hours of sample collection by the following methodologies: ALP²⁰, Pi²¹, Ca⁺⁺²², MDA (TBARS)²³, SOD by Mishra and Fridovich²⁴ and Erythrocyte reduced

glutathione (GSH) by Beutler et al²⁵, GPX by Paglia D.E. et al²⁶, GR by Carlberg I²⁷, Vitamin E (alpha tocopherol)²⁸, Vitamin A(Retinol)²⁸, Vitamin C²⁹.

After estimation of base line osteoblastic markers and antioxidant profile in patients and control, we supplement 180 gm of tomato (products like soup, paste, ketchup) contain 12 mg of lycopene to patients and their blood samples were reassessed for the same parameters after follow up of 90 days lycopene supplementation period.

Statistical analysis was performed using SPSS 14.3, which involves paired and unpaired t-tests. Mean values and \pm SD were calculated for each group and were compared between patients before and after lycopene supplementation. p value <0.05 were taken as point of minimal statistical significance.

Results

The main result of the study revealed significant changes in osteoblastic markers i.e. ALP, Ca⁺⁺, and Pi. ALP showed significant increase 93.3 \pm 5.41 IU/l (P<0.001), ionic calcium showed significant decrease 1.05 \pm 0.39 mmol/l (P<0.001) while no significant change in Inorganic Phosphorus 3.44 \pm 0.61mg/dl (NS). Lipid per oxidation product MDA was found to be increased significantly 6.54 \pm 0.71nmol/ml (p<0.001) where as other antioxidant enzymes and vitamins showed significant decrease as SOD 3.11 \pm 0.72 Units/ml (p<0.01), GPX 47.7 \pm 5.24 Units/gHb (p<0.01), GR 40.04 \pm 6.03 Units/L (p<0.001), GSH 8.17 \pm 1.10Units/gHb (NS), Vitamin A 18.0 \pm 5.72 μ g/dl (p<0.002), Vitamin E 0.35 \pm 0.19mg/dl (p<0.001) and Vitamin C 0.28 \pm 0.13 mg/dl (p<0.01) in osteoporotic patients as compare to control. After supplementation of lycopene osteoblastic marker ALP achieved normal range 90.3 \pm 3.9IU/l (p<0.001), ionic calcium increased significant to the level of 1.29 \pm 0.46mmol/l (p<0.001) while no significant change in Inorganic Phosphorus 3.8 \pm 0.60 mg/dl(NS) was found, lipid per oxidation product MDA significantly decreases 3.89 \pm 0.41 nmol/ml (p<0.001) while other antioxidant enzymes and vitamins showed significant increase as SOD 5.8 \pm 0.68U/ml (p<0.01), GSH 9.15 \pm 0.75U/gHb (p<0.001), Vitamin C 0.69 \pm 0.21mg/dl (p<0.001), Vitamin A 52.01 \pm 10.64 μ g/dl (p<0.002), Vitamin E 0.59 \pm 0.14mg/dl. Levels of GPX 72.9 \pm 7.61 U/gHb (NS), GR 54.9 \pm 6.02Units/L (NS) were not found to be significant. Results of present study shows improved osteoblastic markers, antioxidant profile and decreased lipid peroxidation product in patients after lycopene supplementation.

Table:-1 Levels of Osteoblastic markers, Antioxidant vitamins and enzymes in patients and control.

Parameters	Control	Osteoporotics
Alkaline phosphatase IU/l	71.7 \pm 6.7	93.3 \pm 5.41 ^{**}
Free or ionic Calcium mmol/l	1.33 \pm 0.48	1.05 \pm 0.39 ^{**}
Inorganic Phosphorus mg/dl	3.9 \pm 0.60	3.44 \pm 0.61 ^{NS}
Vit A μ g/dl	52.36 \pm 8.6	18.0 \pm 5.72 [*]
Vit E mg/dl	1.2 \pm 0.37	0.35 \pm 0.19 ^{**}
Vit C mg/dl	0.96 \pm 0.28	0.28 \pm 0.13 [*]
MDA nmol/ml	3.10 \pm 0.69	6.5 \pm 0.71 ^{**}
SOD Units/ml	5.52 \pm 0.66	3.11 \pm 0.72 [*]
GPX Unit/gHb	64.8 \pm 7.46	47.7 \pm 5.24 [*]
GR Unit/L	55.61 \pm 6.4	40.04 \pm 6.03 ^{**}
GSH Unit/gHb	8.72 \pm 0.73	8.17 \pm 1.10 ^{NS}

**** highly significant * significant NS not significant**

Table:-2 Level of Significance of Osteoblastic markers, antioxidant enzymes, vitamins before and after lycopene supplementation in patients.

Parameters	Baseline levels	After Supplementation
Alkaline phosphatase IU/l	93.3±5.41	90±3.9**
Ionic Calcium mmol/l	1.05±0.39	1.29±0.46**
Inorganic Phosphorus mg/dl	3.44±0.61	3.8±0.60 ^{NS}
Vit A µg/dl	18.0± 5.72	52.01±10.64**
Vit E mg/dl	0.35±0.19	0.59±0.14**
Vit C mg/dl	0.28±0.13	0.69±0.21**
MDA nmol/ml	6.5±0.71	3.89±0.41**
SOD Units/ml	3.11±0.72	5.8±0.68*
GPX Unit/gHb	47.7±5.24	72.94±7.61*
GR Unit/L	40.04±6.03	55.2±5.84**
GSH Unit/gHb	8.17±1.10	9.15±0.75**

** highly significant * significant

Chart 1:-Showing levels of osteoblastic markers in both groups





Chart 2:- Showing status of Antioxidant vitamins and enzyme in Control and Patients group before and after supplementation



Discussion

Osteoporosis due to oxidative stress results in excessive free radical formation indicated by increased Malondialdehyde level³⁰ similar results were found in our study. In present study osteoporotic patients showed increased levels of ALP, decreased levels of Ca^{++} with no significant change in Pi. Apart from this, there is a significant decrease in the antioxidant status of the body, reflected by low levels of reduced glutathione (GSH) glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD), Vitamin A, E and C.

In this study included markers of osteoblastic activity and antioxidant status, both enzymatic and nonenzymatic. Normally osteoblast secretes cytokines during oxidative stress, these cytokines induce the activity of osteoclast that secretes acid, an enzyme protease which causes lysis of collagen and bone deformation. Deformation of bone is repaired by osteoblast with the release of enzyme alkaline phosphatase which helps in mineralization of bone by deposition of calciumphosphate³¹ similar trends were found in present study enhanced activity of ALP and decrease in free calcium in osteoporotics with increased oxidative stress.

After lycopene (a potent antioxidant) supplementation levels of free radicals was found to be decreased in the study, reduced levels of free radical leads to decrease osteoclastic activity with decreased bone deformation, less osteoblastic activity and normal ALP levels.

In our study we found increased Ca^{++} levels after lycopene supplementation, the reason could be, increased levels of ALP nullify the effect of pyrophosphatase (enzyme that prevent the precipitation of calcium) which leads to increased deposition of calcium as calcium phosphate in the bone³² but after lycopene supplementation decrease in oxidative stress leads to decreased osteoblastic activity, less ALP formation and release therefore there is significant increase in Ca^{++} as compared to before supplementation of lycopene in osteoporotics with no significant change in inorganic phosphate.

In present study serum MDA is significantly increases in patients suffering from osteoporosis as compared to control, it is in accordance to previous findings that in osteoporosis decreased in osteoblastic activity leads to increase in osteoclastic activity (cells responsible for bone resorption) resulting in excessive free radical formation and these reactive oxygen species degrade polyunsaturated lipids, forming malondialdehyde. This compound is a reactive aldehyde, production of MDA is used as a biomarker to measure the activity of osteoclast in osteoporotic patients.^{30,33} Serum SOD activity is significantly decrease in patient group as compare to control simply stated, SOD outcompetes damaging reactions of superoxides released by osteoclast thus protecting osteoblast from superoxide toxicity.^{34,35}

Glutathione peroxidase(GPx) and reductase(GR) are two enzymes; GSH is the substrate for them. In this study, lycopene supplementation also increased the levels of reduced glutathione the most important antioxidant metabolite that plays an important role in maintaining significant levels of GPX activity. This is the main enzyme involved in removing the H₂O₂ generated from dismutation of anions by SOD.GSH is also the cofactor of several reducing enzyme such as ascorbate reductase and endoperoxidase isomerase.

The above results suggested that tomato lycopene reduces lipid peroxidation rate by acting as a good chain breaking antioxidant, which reacts with peroxides formed in the propagation phase of lipid peroxidation to form carbon centered radicals. These radical reacts readily and reversibly with oxygen to form new chain carrying peroxile radicals which are stable than.³⁶

Antioxidant Vitamins work with the synergy of antioxidant enzymes, Vitamin E and vitamin A are most important chain breaking antioxidants and they protect polyunsaturated fatty acids from peroxidative damage by donating hydrogen to the lipid peroxy radical.^{37,38} Because of the lipophilic property of the tocopherol, it is the major free radical chain terminator in the lipophilic environment and proven protective against hip fracture.³⁹ Vitamin C act as a reducing and antioxidant agent directly reacts with superoxides, hydroxyl radicals, and various lipid hydroperoxides.⁴⁰ it has positive role in bone health as vitamin C is a cofactor in the maturation of collagen.⁴¹

The oxidative stress was drastically reduced and antioxidant status was improved by supplementation of lycopene. As an antioxidant lycopene has a singlet oxygen quenching ability twice as high as that of β -carotene and 10 times higher that of α -tocopherol,¹⁴ lycopene participate in a host of chemical reactions to protect critical cellular biomolecules including lipid, proteins and DNA.^{15,16} lycopene create first line of defense against free radicals so it protect all the antioxidant enzyme and vitamins from oxidative damage thus there is improvement in the levels of all antioxidants after lycopene supplementation.

In addition lycopene supplementation in the form of tomatoes provide other dietary antioxidants like Vitamin C, A, E. These dietary antioxidants contribute for the improvement of bone health and play vital role in the recovery of disease.

Conclusion

The above observations show a significant decrease in oxidative stress with maintenance of osteoblastic cell activity after lycopene supplementation in the form of tomatoes. Lycopene in tomatoes allows for 90% of the total carotenoids and other phytochemicals with other dietary antioxidant vitamins uses for good bone health the study also suggest that body's internal production of antioxidant is not enough to neutralize all free radicals so increased dietary intake of potent antioxidant like lycopene in the form of tomato products is essential to maintain good bone

health. Tomato lycopene is easily for low socioeconomic group which plays an important role in treatment and prevention of osteoporosis in developing country like India.

References

1. Chan GK, Duque G. Age-related bone loss: old bone, new facts. *Gerontology* 2002; 48: 62-71.
2. Mundy GR. Bone Remodeling. In: MJ F, ed. *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*. New York: Lippincott, Williams & Wilkins 1999; 30-38.
3. Raisz LG. Bone cell biology: new approaches and unanswered questions. *J Bone Min Res* 1993; 8: S457-S65.
4. Lindsay R, Cosman F. Prevention of Osteoporosis. In: Favus MJ, ed. *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*. New York: Lippincott Williams & Wilkins 1999; 264-70.
5. Consensus Development Conference Diagnosis, prophylaxis and treatment of osteoporosis. *Am J Med* 1993; 94 :646-50.
6. Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. *J Bone Miner Res* 1996; 11(3): 337-49.
7. Gupta A. Osteoporosis in India –the nutritional hypothesis. *Nalt Med J India*1996; 9(6): 268-74.
8. Osteoporosis tutorials: The internet pathology laboratory :citation: <http://www.library.med.utah.edu/web/path/tutorial/oateo/ostpro.html>
9. Andrew E, Rosenberg MD. Skeletal system and soft tissue tumors. In: Cotran RS, Kumar V, Robbins S L and Schoen FJ, editors. *Pathologic Basis of Disease*, 5th Ed. W B Saunders Co. Philadelphia, USA 1994; 1220-21.
10. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: An overview. *Meth Enzymol* 1990; 186: 1–85.
11. Favier AE, Cadet J, Kalyanaraman B, Fontecave M, Pierre J-L (eds). "Analysis of Free Radicals in Biological Systems." Basel, Switzerland: Birkhäuser Verlag 1995; pp 83–98.
12. Ames BN, Gold LS, Willet WC. Causes and prevention of cancer. *Proc Natl Acad Sci USA* 1995; 92: 5258–5265.
13. Witztum JL. The oxidation hypothesis of atherosclerosis. *Lancet* 1994; 344: 793–795.
14. Di Mascio P, Kaiser S, Sies H. Lycopene as the most effective biological carotenoid singlet oxygen quencher. *Arch Biochem Biophys* 1989; 274: 532–538.
15. Rao AV, Agarwal S. Role of lycopene as antioxidant carotenoid in the prevention of chronic diseases: a review. *Nutr Res* 1999; 19: 305–323.
16. Stahl W, Sies H. Lycopene: a biologically important carotenoid for humans? *Arch Biochem Biophys* 1996; 336: 1–9.
17. Stahl W, Sies H. Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato juice in humans. *J Nutr* 1992; 122: 2161–2166.
18. Gärtner C, Stahl W, Sies H. Lycopene is more bioavailable from tomato paste than from fresh tomatoes. *Am J Clin Nutr* 1997; 66: 116–122.
19. Clinton SK. Lycopene: chemistry, biology, and implications for human health and disease. *Nutr Rev* 1998; 56: 35–51.
20. Burtis and Ashwood. *Teitz textbook of Clinical Chemistry*, 3rd ed. W.B. Saunders Co Philadelphia PA 1999; 1351- 52.

21. Fiske CH, Subarrow Y, Harold Varely's Practical Clinical biochemistry, 4th ed. Delhi, India: CBS Publishers and Distributors 1975; 446-7.
22. Bowers GN, Jr Brassad C, Sena SF. Measurement of ionized calcium levels in serum with ion selective electrodes. A mature technology that can meet the daily service needs. *Clin Chem* 1986; 32: 1437-44.
23. Satoh K. Serum lipid peroxide in cerebrovascular disorder determined by a new colorimetric method. *Clin Chim Acts* 1978; 90: 37-43.
24. Mishra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and simple assay for superoxide dismutase. *J Biol Chem* 1972; 247: 3170-5.
25. Beutler E, Duron O, Kelly BM. Improved method for determination of blood glutathione. *J Lab Clin Med* 1963; 61: 882-8.
26. Paglia D E and Valentine W N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J Lab Clin Med* 1967; 70: 158-169.
27. Carlberg I, Mannervik B. Glutathione reductase. *Meth Enzymol* 1985; 113: 484-90.
28. Nierenberg DW, Nann SL. A method for determining concentration of retinol, tocopherol, and five carotenoids in human plasma and tissue samples. *Am J Clin Nutr* 1992; 56: 417-426.
29. Baker W.L. and Lowe T. Sensitive ascorbic acid assay for the analysis of pharmaceutical products and fruit juices. *Analyst* 1985; 110: 1189-1191.
30. Del Rio D, Stewart AJ, Pellegrini N. "A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress". *Nutr Metab Cardiovasc Dis* 2005; 15 (4): 316-28.
31. Bellows CG, Aubin JE, Heersche JNR. Initiation and progression in mineralization of bone nodules formed in vitro: the role of alkaline phosphatase and organic phosphate. *Bone Miner* 1991; 14: 27-40.
32. Magnusson P, Larsson L, Magnusson M, Davie MWJ, Sharp CA. Isoforms of bone alkaline phosphatase: Characterization and origin in human trabecular and cortical bone. *J Bone Miner Res.* 1999; 14: 1926-33.
33. Murray RK, Keeley FW. The extracellular matrix: osteoporosis. In: Murray RK, Granner DK, Mayes PA, Rodwell VW, Harper's biochemistry, 25th ed; 57 Lange medical Books, Stamford, Connecticut: McGraw Hill 2000; 710-11.
34. Landis G. N. & Tower J. Superoxide dismutase evolution and life span regulation. *Mech. Ageing Dev* 2005; 126: 365-379.
35. Yang S, Ries WL, Key Jr. NADP oxidase in the formation of superoxide in osteoclasts. *Calcific Tissue Int* 1998; 63: 346-50.
36. Shen D, Dalton T. P, Nebert D W & Shertzer H G. Glutathione redox state regulates mitochondrial reactive oxygen production. *J Biol Chem* 2005; 280: 25305-25312.
37. Weber P, Bendich A, Machlin LJ. Vitamin E and human health: Rationale for determining recommended intake levels. *Nutrition* 1997; 13(5): 450-460.
38. Burton G W, & Ingold K U. Beta-carotene - An unusual type of lipid antioxidant. *Science* 1984; 224:569-573.
39. Melhus H, Michaelsson K, Holmberg L, Wolk A, Ljunghall S. Smoking antioxidant Vitamins, and the risk of hip fracture. *J Bone Miner Res* 1999; 14: 129-135.
40. Carr A, & Frei B. Does Vitamin C act as a pro-oxidant under physiological conditions? *FASEB J* 1999; 13: 1007-1024.
41. Franceschi R, Iyer B. Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells. *J Bone Miner Res* 1992; 7: 235-246.